This trial is evaluating whether Medically-Tailored Meals (MTMs) will improve 5 primary outcomes and 3 secondary outcomes in patients with Heart Failure. Measurement will happen over the course of Change from start to end of 12-week MTM period.
This trial requires 16 total participants across 2 different treatment groups
This trial involves 2 different treatments. Medically-Tailored Meals (MTMs) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Given these results, our data suggest that patients with moderate functional limitations, who have low to no comorbidities and who do not have contraindications to a clinical trial may be considered." - Anonymous Online Contributor
"Each year, around 2 million adults in the United States are diagnosed with new Type I or Type II diabetes. This makes up 2.1% of American adults. Around 2 million new cases of heart failure are diagnosed a year in the United States. This makes it the most common cause of heart failure in adults." - Anonymous Online Contributor
"In the US, 1 in 4 adults has heart failure. This condition will negatively affect a person's quality of life, cause them to go into bankruptcy and result in a reduced life expectancy." - Anonymous Online Contributor
"The causes of heart disease and heart failure are manifold. Heart disease is often referred to as a “cardiovascular disease.” The underlying causes of heart disease and heart failure are quite different, and are not interchangeable. Even where the etiology is known, it is possible to treat heart failure as a cardiogenic shock, as it is not only due to an inability to pump blood efficiently, but there is an underlying disease process." - Anonymous Online Contributor
"The data suggest that neither the degree of myocardial damage, nor the degree of cardiac dysfunction can be considered to be curable with current pharmacologic therapy. The best treatment for heart failure is determined by a multidisciplinary approach, combining knowledge of the pathophysiology of heart failure (in other words, the mechanisms underlying dysfunction of the heart), optimal patient selection and treatment as determined by clinical parameters." - Anonymous Online Contributor
"What signs may be present in heart failure are usually progressive and include shortness of breath, palpitation and low blood pressure. Many, if not most, patients with heart failure have systemic symptoms. Systemic symptoms can include fatigue, feeling tired, difficulty sleeping, increased sweating or weight loss and are common. Signs of heart failure in childhood may not become apparent until heart failure develops as an adulthood illness.\n" - Anonymous Online Contributor
"In addition to ACE inhibitors, beta-blockers are one of a number of common treatments for HF management. Although ACE inhibition may increase survival in some patients with HF and improved cardiac function, it may also increase deaths of patients with poor heart function. In addition, diuretics can be harmful in HF, so avoiding their use when possible is advisable." - Anonymous Online Contributor
"A small number of published systematic reviews were eligible for our analyses. To our knowledge, this is one of the largest, and the only systematic review to incorporate the most recent research in the heart failure field. Data from a recent study are limited in the following ways: 1) some reviews may have omitted studies with some relevant results; 2) other reviews may have omitted some pertinent results; and 3) the studies which were included in these reviews may have undergone a higher degree of journal peer review, and hence be more highly cited than other studies. The lack of such considerations in this review may limit its applicability in the current era." - Anonymous Online Contributor
"A substantial proportion of heart failure patients presenting for care at our institution are of advanced age. While CAD was the most common etiology of heart failure in this large, multi-institution study, the contribution of CAD to heart failure did not increase with age. In this age group, heart failure may be related to coronary heart disease, but is not the result of coronary heart disease. These observations may have important implications for the management of patients with heart failure, particularly those in the elderly." - Anonymous Online Contributor
"The treatment of cachexia is an area that has only recently been tackled by therapeutic methods, and as yet little is known of treatment options. In this context, MTMs will have an important role, both in the therapy of other diseases (e.g. obesity or cachexia), and in its own right. At present, clinical applications for MTMs are currently limited. Results from a recent paper of a large multicenter study were presented at the annual congress of the European Society for Parenteral and Enteral Nutrition in 2003. In particular the possibility is mentioned of investigating MTMs, aimed at prevention and treatment of cachexia, as an alternative or, alternatively, combination of the treatment of rheumatic diseases." - Anonymous Online Contributor
"Although we understand the clinical importance of treating heart failure, there have been few changes in our management. This may reflect a lack of relevant research or the fact the drugs currently available are inadequate to deal with chronic heart failure." - Anonymous Online Contributor
"Cardiac heart failure occurs in people of almost any age. However, the average age at diagnosis is 71, with more women diagnosed than men at 62 years old and more people over 80 years old getting diagnosed by a specialist than getting one found elsewhere." - Anonymous Online Contributor